Canopy Growth Corp vs Tilray Brands Inc — how do they compare? Canopy Growth Corp trades at $1 (market cap $421.10M), while Tilray Brands Inc trades at $4.69 (market cap $649.42M). The key difference: Tilray Brands Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| CGC | TLRY | |
|---|---|---|
Market Cap | $421.10M | $649.42M |
Sector | Health | Health |
52-Week High | $1.92 | $21.00 |
52-Week Low | $0.86 | $3.88 |
Enterprise Value | $378.55M | $816.55M |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
TLRY trades at $4.68, up 5.88% today, amid bullish technical signals and news-driven momentum. The company reported record fiscal 2026 revenue of $915 million but posted a net loss of $121 million, with profitability challenges persisting. Recent developments include new product launches and partnerships, while analyst sentiment remains mixed with a majority hold rating.
Outlook hinges on revenue growth and margin improvement, but risks include sustained losses, high debt, and competitive pressures. The stock offers speculative appeal if execution improves, yet volatility and dilution concerns warrant caution for investors.
Trailing returns across standard periods
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →